Business
SCIB1 Early Immune Effect Observed by ImmunTraCkeR
SCIB1 Early Immune Effect Observed by ImmunTraCkeR.
About this update from Scancell Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 3689L Scancell Holdings Plc 11 January 2016 \n\nEarly Immune Effect of SCIB1 Cancer Vaccine Observed in Blood by ImmunTraCkeR® Companion Diagnostic \n \nImmunTraCkeR® to be incorporated into SCIB1's upcoming Phase II checkpoint inhibitor combination clinical trial \n \nImmunTraCkeR® represents potential companion diagnostic for early detection of patient response to SCIB1 immunotherapy \n \n \nNottingham, UK and Grenoble, France, January 11, 2016 - Scancell Holdings plc ('Scancell' LSE:AIM SCLP), the developer of novel immunotherapies for the treatment of cancer, and immune companion diagnostic developer ImmunID, today released data showing patient immunologic response to cancer vaccine SCIB1 can be demonstrated through monitoring changes in the diversity of T cells found in the blood.\n \nThe collaboration between Scancell and ImmunID to predict SCIB1 responders using ImmunTraCkeR® was announced in a press release on 30 July 2015.\n \n\"This initial data shows promise for the development of ImmunTraCkeR® as a companion diagnostic for SCIB1 cancer immunotherapy\" said Dr Nicolas Pasqual, Co-Founder & Chief Science Officer of ImmunID. \"The ability to identify patient responders to immuno-oncology treatments early is a key unmet clinical need which is likely to improve cancer patient outcomes.\" \n \nProf Lindy Durrant, Joint Chief Executive Officer of Scancell, said: \"These results provide further evidence that SCIB1 can induce T cell responses that are associated with disease control. ImmunTraCkeR® shows promise as an assay for predicting which patients will benefit most from SCIB1 and we are looking forward to conducting additional research on this during our planned checkpoint inhibitor combination trial.\"\n \nDr Bernhard Sixt, Chairman & Chief Executive Officer of ImmunID, added: \"These early but promising results are pointing towards the value ImmunID brings as a partner to biotech companies. We are convinced that ImmunTraCkeR® stratification will help to shorten clinical trial times, accelerate regulatory approval in the field of immuno-oncology and enhance investor confidence.\"\n \nThe data was generated through a pilot study performed in conjunction with Scancell's Phase 1/2 trial of the SCIB1 cancer vaccine in patients with resected s...